



AMERISE BIOSCIENCES LIMITED

CIN: L29199GJ1984PLC007195

(Formerly Known as AMRADEEP INDUSTRIES LIMITED)

Date: 02.02.2026

To,
Listing Department,
BSE Limited,
P J Tower, Dalal Street,
Mumbai-400001

Scrip Code: 531681

Security ID: AMERISE

Sub: Outcome of the Board Meeting of the board held on 2nd February 2026.

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. **Monday 2nd February 2026** at the Registered Office of the Company and transacted the following major businesses:

- 1.) Considered and approved Un-audited financial results for the quarter and nine months ended as on **31st December, 2025**.
- 2.) Considered and approved the appointment of **Mr. Albert Hines (DIN No.: 10742692)** as Wholetime Director and Chief Financial Officer of the Company w.e.f **02.02.2026**
- 3.) Considered and accepted the resignation of **Mr. Dinesh Rathod DIN No.: 9406871** from the post of Wholetime director and Chief Financial Officer of the Company **w.e.f 02.02.2026**

The board meeting commenced at **03:45 PM** and concluded at **04:15 PM**

Please take the above intimation in your records.

Thanking You.

For, AMERISE BIOSCIENCES LIMITED

Albert Hines
Wholetime Director



AMERISE BIOSCIENCES LIMITED

CIN: L29199GJ1984PLC007195

(Formerly Known as AMRADEEP INDUSTRIES LIMITED)

The particulars for appointment of **Mr. Albert Hines** as **Whole-time Director and Chief Financial Officer of the Company** (Key Managerial Personnel) are as under:

Name of the Key Managerial Personnel (KMP)	Mr. Albert Hines
Reason for Change viz. appointment, resignation, removal, death or otherwise;	Appointment
Date of Appointment	02.02.2026
Brief Profile	Mr. Albert Hines is 25 years old and has experience of more than 3 years in the field Of accounts and finance.
Disclosure of relationship between Directors (in case appointment as a Director)	Not Applicable
Initial Disclosures as per Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015	Percentage of Holding in the Shares of Company
Mr. Albert Hines	Nil

The particulars for resignation of **Mr. Dinesh Rathod** from designation of Whole time Director and Chief Financial Officer (Key Managerial Personnel) are as under:

Name of the Key Managerial Personnel (KMP)	Mr. Dinesh Rathod
Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation due to personal commitments
Confirmation that there is no other material reasons other than those provided	Not Applicable
Date of Cessation	02.02.2026
Names of listed entities in which the resigning director holds directorships	No

DINESH RATHOD

Date: 02.02.2026

To
The Board of Directors,
AMERISE BIOSCIENCES LIMITED
AHMEDABAD

RE: RESIGNATION

I hereby tender my resignation as a Whole Time Director & Chief Financial Officer of the Company due to pre-occupation with other work and request you to put up the same before the meeting of the Board of Directors of the Company. I also request you to give a notice of my resignation to the Registrar of Companies, Ahmedabad, and Gujarat.

I thank the other members on the Board for giving me the co-operation and assistance to discharge my duties during my tenure as a Director of the Company.

Board of Directors,
AMERISE BIOSCIENCES LIMITED
AHMEDABAD

Yours faithfully,

DINESH RATHOD
DIN: 09406871
Date: 02.02.2026

I thank the other members on the Board for giving me the co-operation and assistance to discharge my duties during my tenure as a Director of the Company.

Board of Directors,
AMERISE BIOSCIENCES LIMITED
AHMEDABAD

Yours faithfully,
DINESH RATHOD
DIN: 09406871
Date: 02.02.2026

I thank the other members on the Board for giving me the co-operation and assistance to discharge my duties during my tenure as a Director of the Company.

ON

I hereby tender my resignation as a Whole Time Director & Chief Financial Officer of the Company due to pre-occupation with other work and request you to put up the same before the meeting of the Board of Directors of the Company. I also request you to give a notice of my resignation to the Registrar of Companies, Ahmedabad, and Gujarat.

I thank the other members on the Board for giving me the co-operation and assistance to discharge my duties during my tenure as a Director of the Company.

ON

I hereby tender my resignation as a Whole Time Director & Chief Financial Officer of the Company due to pre-occupation with other work and request you to put up the same before the meeting of the Board of Directors of the Company. I also request you to give a notice of my resignation to the Registrar of Companies, Ahmedabad, and Gujarat.

I thank the other members on the Board for giving me the co-operation and assistance to discharge my duties during my tenure as a Director of the Company.

Amerise Biosciences Limited

CIN:- L29199GJ1984PLC007195

Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014

Email:- amradeepindustries@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended December 31, 2025

(Rs. In lacs)

Sl No.	Particulars	Quarter Ended 31 Dec'2025	Quarter Ended 30 Sept'2025	Quarter Ended 31 Dec'2024	Nine Months Ended 31 Dec'2025	Nine Months Ended 31 Dec'2024	Year Ended 31 Mar 2025
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
(a)	Revenue from Operations	-	-	-	-	-	-
(b)	Other Income	4.49	6.75	-	17.60	0.00	18.80
	Total Income from Operations (Net)	4.49	6.75		17.60	0.00	18.80
2	Expenses						
(a)	Cost of material consumed	-	-	-	-	-	-
(b)	Purchase of stock in trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	1.80	1.80	0.97	5.92	2.21	10.19
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-	-	-
(g)	Other expenses	1.72	9.18	0.63	15.75	7.63	7.86
	Total Expenses	3.52	10.98	1.59	21.67	9.83	18.04
3	Profit / (Loss) from operations before exceptional items and Tax (1-2)	0.97	(4.23)	(1.59)	(4.07)	(9.83)	0.76
4	Exceptional Items						
5	Profit / (Loss) before Tax (3 ± 4)	0.97	(4.23)	(1.59)	(4.07)	(9.83)	0.76
6	Tax Expense	-	-	-	-	-	0.19
7	Profit / (Loss) after tax (5 - 6)	0.97	(4.23)	(1.59)	(4.07)	(9.83)	0.57
8	Other comprehensive income (Net of Tax)						
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or	-	-	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
9	Total comprehensive income (7 ± 8)	0.97	(4.23)	(1.59)	(4.07)	(9.83)	0.57
10	Paid-up equity share capital (Face Value of Rs.1/- each)	660.69	660.69	660.69	660.69	660.69	660.69
11	Other Equity						(122.71)
12	Earnings Per Share (before extraordinary items) (of Rs. 1/- each) (not annualised):						
	(a) Basic	0.00	(0.01)	(0.00)	(0.01)	(0.01)	0.00
	(b) Diluted	0.00	(0.01)	(0.00)	(0.01)	(0.01)	0.00

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 02, 2026. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board

Place : Ahmedabad

Date : 02nd February, 2026

Albert Hines
Wholetime Director



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
AMERISE BIOSCIENCES LIMITED
Ahmedabad

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of AMERISE BIOSCIENCES LIMITED ("the Company"), for the Quarter ended on December 31, 2025 and year to date result for the period from 01 April, 2025 to 31 December, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS 34") "Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) and



other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509 W


CA Amit Shah
Partner
M. No.: 126337
UDIN: 26126337IBTUU3501
Place: Vadodara
Date: 02.02.2026

